Automate Your Wheel Strategy on NVO
With Tiblio's Option Bot, you can configure your own wheel strategy including NVO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NVO
- Rev/Share 70.1487
- Book/Share 37.7947
- PB 9.3335
- Debt/Equity 0.5906
- CurrentRatio 0.784
- ROIC 0.3934
- MktCap 1567501674741.4292
- FreeCF/Share 13.9401
- PFCF 25.2868
- PE 14.1233
- Debt/Assets 0.2059
- DivYield 0.0303
- ROE 0.7786
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | NVO | HSBC Securities | Hold | Buy | -- | -- | Oct. 1, 2025 |
| Downgrade | NVO | Morgan Stanley | Equal Weight | Underweight | -- | $47 | Sept. 29, 2025 |
| Upgrade | NVO | Berenberg | Hold | Buy | -- | -- | Sept. 17, 2025 |
| Upgrade | NVO | Rothschild & Co Redburn | Neutral | Buy | -- | -- | Sept. 16, 2025 |
| Upgrade | NVO | Bernstein | Market Perform | Outperform | -- | -- | Sept. 9, 2025 |
| Upgrade | NVO | BNP Paribas Exane | Underperform | Neutral | -- | $54 | Aug. 13, 2025 |
| Downgrade | NVO | UBS | Buy | Neutral | -- | -- | Aug. 5, 2025 |
| Downgrade | NVO | HSBC Securities | Buy | Hold | -- | $57 | July 31, 2025 |
| Downgrade | NVO | Barclays | Overweight | Equal Weight | -- | -- | July 30, 2025 |
| Downgrade | NVO | BMO Capital Markets | Outperform | Market Perform | -- | $64 | April 17, 2025 |
News
Novo Nordisk Slumps As It Cautions 'Unsafe And Unlawful' Knockoffs Will Pressure Wegovy
Published: August 06, 2025 by: Investors Business Daily
Sentiment: Negative
Novo Nordisk stock slumped Wednesday after saying it expects compounded versions to undercut sales of its obesity drug, Wegovy.
Read More
Novo Nordisk expands legal action to protect patients from non-FDA approved weight-loss drugs
Published: August 05, 2025 by: CNBC Television
Sentiment: Neutral
CNBC's Brandon Gomez and Angelica Peebles join 'Power Lunch' to break down the biggest headlines in the pharmaceutical space.
Read More
Berger Montague PC Announces Class Action Filed Against Novo Nordisk A/S (NYSE: NVO) for Alleged Securities Violations
Published: August 05, 2025 by: PRNewsWire
Sentiment: Neutral
PHILADELPHIA , Aug. 5, 2025 /PRNewswire/ -- Berger Montague PC is investigating claims under the federal securities laws against Novo Nordisk A/S (NYSE: NVO) ("Novo" or the "Company"), a global pharmaceutical company, headquartered in Denmark, after a class action lawsuit was filed against Novo. Investor Deadline: Investors who purchased or acquired Novo securities between May 7, 2025 through July 28, 2025 (the "Class Period"), may, no later than September 30, 2025 , seek to be appointed as a lead plaintiff representative of the class.
Read More
Novo Nordisk expands lawsuits against weight-loss drug compounders
Published: August 05, 2025 by: Reuters
Sentiment: Neutral
Danish drugmaker Novo Nordisk said on Tuesday it has filed 14 new lawsuits in the United States against the sale of unapproved versions of semaglutide, the main ingredient in its popular weight-loss and diabetes drugs, Wegovy and Ozempic.
Read More
Rosen Law Firm Urges Novo Nordisk A/S (NYSE: NVO) Investors with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
Published: August 05, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that an investor filed a class action lawsuit on behalf of purchasers and acquirers of Novo Nordisk A/S (NYSE: NVO) securities between May 7, 2025 and July 28, 2025, both dates inclusive (the “Class Period”). Novo Nordisk is a pharmaceutical company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegat.
Read More
Weighing HIMS GLP-1 Trends, NVO Partnership & Other Businesses
Published: August 05, 2025 by: Schwab Network
Sentiment: Neutral
Michael Cherny sees opportunity for Hims & Hers (HIMS), as long as it can overcome headwinds facing its non-weight loss businesses. He argues the stock hasn't traded on fundamentals and weighs heavily on its GLP-1 drugs sales.
Read More
Novo Nordisk Stock Catches a Downgrade. The Eli Lilly Threat Is Just One Reason.
Published: August 05, 2025 by: Barrons
Sentiment: Negative
Novo Nordisk stock was downgraded to Neutral from Buy by UBS analysts, who cited the threat posed by its U.S. rival.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S - NVO
Published: August 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
Published: August 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Novo To Contact Him Directly To Discuss Their Options
Read More
Berger Montague PC Investigating Claims on Behalf of Novo Nordisk A/S (NYSE: NVO) After Class Action Filing
Published: August 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
PHILADELPHIA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against Novo Nordisk A/S (NYSE: NVO) (“Novo” or the “Company”) on behalf of investors who purchased or otherwise acquired publicly traded securities of Novo from May 7, 2025 through July 28, 2025 (the “Class Period”).
Read More
Watch These Novo Nordisk Stock Price Levels After Last Week's 33% Drop
Published: August 04, 2025 by: Investopedia
Sentiment: Positive
Novo Nordisk's (NVO) U.S.-listed shares were up about 2% in recent trading after shedding about a third of their value last week, when the company cut its full-year outlook and named a new CEO, leading Wall Street analysts to downgrade the stock.
Read More
Will These 5 Pharma, Biotech Bigwigs Surpass Q2 Earnings Forecasts?
Published: August 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Let's look at five pharma and biotech companies, PFE, LLY, AMGN, GILD and NVO, which are scheduled to release their second-quarter 2025 results this week.
Read More
Novo Nordisk Before Q2 Earnings: How Should Investors Play the Stock?
Published: August 04, 2025 by: Zacks Investment Research
Sentiment: Neutral
NVO's second-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, Wegovy, Ozempic and Rybelsus.
Read More
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
Published: August 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Novo To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Novo between May 7, 2025, to July 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Novo Nordisk A/S (“Novo” …
Read More
Novo Nordisk's Alhemo Wins FDA Nod, Expanding Subcutaneous Option For Hemophilia Patients
Published: August 01, 2025 by: Benzinga
Sentiment: Positive
The U.S. Food and Drug Administration approved on Friday, the Novo Nordisk A/S NVO Alhemo (concizumab-mtci) injection as a once-daily prophylaxis to prevent or reduce the frequency of bleeding episodes in patients 12 years of age and older with hemophilia A or B without inhibitors.
Read More
Novo Nordisk: Don't Miss Buying This Dip
Published: July 30, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk's 20%+ price drop since yesterday following a significant downgrade in sales and profit guidance is a great buying opportunity. The stock's forward P/E is at half the stock's five-year average, and with growth catalysts in place, fundamentals could improve too. The launch of NovoCare is showing signs of boosting Wegovy's sales, and the E.U.-U.S. trade deal adds stability for the new CEO.
Read More
Securities Fraud Investigation Into Novo Nordisk A/S (NVO) Continues – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
Published: July 30, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz continues its investigation of Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON NOVO NORDISK A/S (NVO), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On June 23, 2025, Novo Nordisk announced that it was ending its partn.
Read More
Rosen Law Firm Encourages Novo Nordisk A/S Investors to Inquire About Securities Class Action Investigation – NVO
Published: July 30, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Novo Nordisk A/S (NYSE: NVO) resulting from allegations that Novo Nordisk may have issued materially misleading business information to the investing public. So What: If you purchased Novo Nordisk securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangem.
Read More
Can Novo Nordisk's New CEO Stop Rivals From Taking Over the Anti-Obesity Market?
Published: July 30, 2025 by: WSJ
Sentiment: Neutral
The company's first non-Danish leader, Maziar Mike Doustdar, will face a challenging landscape in the U.S.
Read More
Novo Nordisk: After the profit warning what next?
Published: July 30, 2025 by: Proactive Investors
Sentiment: Negative
Shares in Novo Nordisk (NYSE:NVO) are under the spotlight after a surprise profit warning, which, while denting the share price, failed to the wreak the damage some might have feared. That said, the 3.6% fall in the stock piles on the pain for the Ozempic maker, which was formerly Europe's most valuable company.
Read More
Novo Nordisk Stock Got Battered. Think Twice Before Buying the Dip.
Published: July 30, 2025 by: Barrons
Sentiment: Negative
The maker of Ozempic and Wegovy just had its worst day since Black Monday 1987
Read More
Novo Nordisk: Catch That Falling Knife
Published: July 30, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk's stock has dropped over 20%, but its core business remains strong and diversified, making this an attractive entry point for investors. Despite increased GLP-1 competition and lowered guidance, Novo Nordisk continues to grow, expand its market share, and generate robust cash flow. The company's rare disease and oral semaglutide segments are showing promising growth, with a strong R&D pipeline supporting future expansion.
Read More
Novo Nordisk shares fall further as new CEO faces US challenges
Published: July 30, 2025 by: Reuters
Sentiment: Negative
Shares in Wegovy maker Novo Nordisk continued to slide on Wednesday as analysts warned of persistent competition from copycat drugs in the U.S., a day after a profit warning and the naming of a new CEO prompted investors to wipe $70 billion off the drugmaker's value.
Read More
Novo Nordisk: Massive Overreaction Presents An Opportunity
Published: July 29, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk's sharp selloff is an overreaction; long-term fundamentals remain solid despite lowered guidance and a sudden CEO change. US market headwinds, competitive pressure from Eli Lilly and telehealth, and regulatory loopholes are weighing on near-term growth. Novo Nordisk boasts a robust pipeline with promising obesity and diabetes drugs, including oral Wegovy and next-generation therapies.
Read More
Novo Nordisk's Downgraded Expectations - What The Market Is (Obviously) Missing
Published: July 29, 2025 by: Seeking Alpha
Sentiment: Negative
Novo Nordisk A/S shares plunged after a Q2 revenue update and 2025 guidance downgrade, despite strong double-digit sales and profit growth. The market is concerned about headwinds for semaglutide (Wegovy/Ozempic), including supply issues, competition, and regulatory risks. Despite the selloff, I believe Novo remains undervalued given its dominant GLP-1 franchise, robust pipeline, and long-term growth potential.
Read More
Wegovy maker Novo's profit warning wipes out $70B in market value after shares plunge 30%
Published: July 29, 2025 by: New York Post
Sentiment: Neutral
Novo, which became Europe's most valuable listed company following the launch of Wegovy in 2021, is now facing a reckoning as it looks to turn things around after the abrupt removal in May of CEO Lars Fruergaard Jorgensen.
Read More
NVO stock: Why did Novo Nordisk shares drop 20% today—and who is Maziar Mike Doustdar?
Published: July 29, 2025 by: Fast Company
Sentiment: Negative
Health-related stocks are not having a good day. First, America's largest health insurance provider, UnitedHealth Group (NYSE: UNH), saw its stock drop more than 4% this morning after the company announced disappointing second-quarter results and a full-year 2025 forecast that concerned investors.
Read More
Don't buy the dip in Novo Nordisk yet, says Mizuho's Jared Holz
Published: July 29, 2025 by: CNBC Television
Sentiment: Negative
Jared Holz, Mizuho health care equity strategist, joins 'Money Movers' to discuss Novo Nordisk sinking on guidance cut and his outlook for the stock.
Read More
Ozempic Maker Novo Nordisk Is Plunging 20%. Time to Sell or Buy More?
Published: July 29, 2025 by: 24/7 Wall Street
Sentiment: Negative
Key Points in This Article: Novo Nordisk's (NVO) operations update reported 18% sales and 29% operating profit growth for H1 2025, but one-off adjustments inflated results.
Read More
Novo Nordisk sinks on guidance cut
Published: July 29, 2025 by: CNBC Television
Sentiment: Negative
CNBC's Angelica Peebles joins 'Squawk on the Street' with the latest details on Novo Nordisk's earnings, why the stock is under pressure, and much more.
Read More
About Novo Nordisk A/S (NVO)
- IPO Date 1981-04-30
- Website https://www.novonordisk.com
- Industry Drug Manufacturers - General
- CEO Lars Fruergaard Jorgensen
- Employees 77406